aspirin has been researched along with Autoimmune Thrombocytopenia in 13 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Patients with coronavirus disease 2019 (COVID-19) from novel coronavirus (SARS-CoV-2) infection may present with immune thrombocytopenia (ITP)." | 1.62 | Immune thrombocytopenia following multisystem inflammatory syndrome in children (MIS-C) - a case series. ( Grimes, AB; Kok, EY; Muscal, E; Sexson Tejtel, SK; Srivaths, L; Vogel, TP, 2021) |
| "A 37-year-old woman with idiopathic thrombocytopenic purpura (ITP) suffered from multiple trauma scheduled for open reduction and internal fixation for right tibial and left radius fracture five days after SAE." | 1.48 | Bilateral visual loss and cerebral infarction after spleen embolization in a trauma patient with idiopathic thrombocytopenic purpura: A case report. ( Chen, JY; Hung, KC; Lan, KM; Li, YY; Lin, WC; Sun, CK; Wang, WT, 2018) |
| "Five warfarin-treated patients had five significant bleeding events (0." | 1.28 | Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients. ( Brewer, PM; Rosove, MH, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (15.38) | 18.2507 |
| 2000's | 3 (23.08) | 29.6817 |
| 2010's | 6 (46.15) | 24.3611 |
| 2020's | 2 (15.38) | 2.80 |
| Authors | Studies |
|---|---|
| Puram, RV | 1 |
| Erdil, RM | 1 |
| Weber, BN | 1 |
| Knelson, EH | 1 |
| Van Beuningen, AM | 1 |
| Wallwork, R | 1 |
| Gilyard, SN | 1 |
| Curtis, BR | 1 |
| Ranganathan, R | 1 |
| Leaf, RK | 1 |
| Malhotra, R | 1 |
| Kok, EY | 1 |
| Srivaths, L | 1 |
| Grimes, AB | 1 |
| Vogel, TP | 1 |
| Sexson Tejtel, SK | 1 |
| Muscal, E | 1 |
| Wang, WT | 1 |
| Li, YY | 1 |
| Lin, WC | 1 |
| Chen, JY | 1 |
| Lan, KM | 1 |
| Sun, CK | 1 |
| Hung, KC | 1 |
| Zaid, G | 1 |
| Dawod, S | 1 |
| Rosenschein, U | 1 |
| Li-Sha, G | 1 |
| Peng, C | 1 |
| Yue-Chun, L | 1 |
| Rayoo, R | 1 |
| Sharma, N | 1 |
| van Gaal, WJ | 1 |
| Perera, M | 1 |
| Suarez, A | 1 |
| Luzardo, H | 1 |
| Lopez, J | 1 |
| Molero, T | 1 |
| Choi, WJ | 1 |
| Kim, MJ | 1 |
| Kim, C | 1 |
| Sohn, JH | 1 |
| Choi, HC | 1 |
| Stouffer, GA | 1 |
| Hirmerova, J | 1 |
| Moll, S | 1 |
| Rubery, B | 1 |
| Napoli, M | 1 |
| Ohman, EM | 1 |
| Simpson, R | 1 |
| Hereng, T | 1 |
| Lambert, M | 1 |
| Hachulla, E | 1 |
| Samor, M | 1 |
| Dubucquoi, S | 1 |
| Caron, C | 1 |
| Launay, D | 1 |
| Morell-Dubois, S | 1 |
| Queyrel, V | 1 |
| Hatron, PY | 1 |
| Hirayama, Y | 1 |
| Koda, H | 1 |
| Matsumoto, S | 1 |
| Nakasawa, O | 1 |
| Kuga, T | 1 |
| Takayanagi, N | 1 |
| Efuku, S | 1 |
| Nobuoka, J | 1 |
| Mochizuki, T | 1 |
| Baron, BW | 1 |
| Martin, MS | 1 |
| Sucharetza, BS | 1 |
| Jeon, H | 1 |
| Baron, JM | 1 |
| Rosove, MH | 1 |
| Brewer, PM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Comparison of Clopidogrel-based Antiplatelet Therapy Versus Warfarin as Secondary Prevention Strategy for AntiPhospholipid Syndrome-related STROKE (APS-STROKE)[NCT05995600] | Phase 4 | 400 participants (Anticipated) | Interventional | 2023-12-31 | Not yet recruiting | ||
| Apixaban for the Secondary Prevention of Thromboembolism: a Prospective Randomized Outcome Pilot Study Among Patients With the AntiphosPholipid Syndrome[NCT02295475] | Phase 4 | 48 participants (Actual) | Interventional | 2014-12-10 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for aspirin and Autoimmune Thrombocytopenia
| Article | Year |
|---|---|
Recurrent acute coronary syndrome and restenosis after percutaneous coronary intervention in a patient with idiopathic thrombocytopenic purpura: a case report and literature review.
Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Aspirin; Clopidogrel; Coronary Angiography; Drug-Elut | 2015 |
Four patients with both thrombotic thrombocytopenic purpura and autoimmune thrombocytopenic purpura: the concept of a mixed immune thrombocytopenia syndrome and indications for plasma exchange.
Topics: Adult; Arthritis, Rheumatoid; Aspirin; Autoimmune Diseases; Blood Platelets; Combined Modality Thera | 2001 |
11 other studies available for aspirin and Autoimmune Thrombocytopenia
| Article | Year |
|---|---|
Thrombocytopenia and Thromboses in Myocardial Infarction Associated with Eptifibatide-Dependent Activating Antiplatelet Antibodies.
Topics: Antigens, Human Platelet; Arginine; Aspirin; Autoantibodies; Combined Modality Therapy; Coronary Thr | 2020 |
Immune thrombocytopenia following multisystem inflammatory syndrome in children (MIS-C) - a case series.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Child; COVID-19; Disease Management; Glucocorticoi | 2021 |
Bilateral visual loss and cerebral infarction after spleen embolization in a trauma patient with idiopathic thrombocytopenic purpura: A case report.
Topics: Adult; Aspirin; Blindness, Cortical; Brain Ischemia; Embolization, Therapeutic; Female; Humans; Magn | 2018 |
Immune thrombocytopenic purpura and myocardial infarction: a dilemma of management.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Disease Management; Fema | 2013 |
A case of acute stent thrombosis during treatment with the thrombopoietin receptor agonist peptide--romiplostim.
Topics: Acute Disease; Aspirin; Chest Pain; Clopidogrel; Eptifibatide; Female; Humans; Middle Aged; Peptides | 2012 |
Spontaneous remission after a year of romiplostim in an adult patient with refractory primary immune thrombocytopenia.
Topics: Antibodies, Monoclonal, Murine-Derived; Anticoagulants; Aspirin; Clopidogrel; Drug Resistance; Hemor | 2012 |
Acute cerebellar infarction associated with intravenous gammaglobulin treatment in idiopathic thrombocytopenic purpura.
Topics: Aspirin; Brain Infarction; Cerebellum; Cerebral Angiography; Female; gamma-Globulins; Humans; Immuno | 2012 |
Percutaneous coronary intervention in a patient with immune thrombocytopenia purpura.
Topics: Aged; Angioplasty, Balloon; Aspirin; Clopidogrel; Coronary Angiography; Coronary Stenosis; Eptifibat | 2004 |
Influence of aspirin on the clinical outcomes of 103 anti-phospholipid antibodies-positive patients.
Topics: Adult; Antibodies, Anticardiolipin; Antiphospholipid Syndrome; Aspirin; Disease Progression; Female; | 2008 |
[A case of Evans's syndrome with antiphospholipid antibody syndrome].
Topics: Anemia, Hemolytic, Autoimmune; Anti-Inflammatory Agents; Antiphospholipid Syndrome; Aspirin; Female; | 1996 |
Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients.
Topics: Aged; Antiphospholipid Syndrome; Aspirin; Drug Therapy, Combination; Female; Follow-Up Studies; Hepa | 1992 |
Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients.
Topics: Aged; Antiphospholipid Syndrome; Aspirin; Drug Therapy, Combination; Female; Follow-Up Studies; Hepa | 1992 |
Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients.
Topics: Aged; Antiphospholipid Syndrome; Aspirin; Drug Therapy, Combination; Female; Follow-Up Studies; Hepa | 1992 |
Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients.
Topics: Aged; Antiphospholipid Syndrome; Aspirin; Drug Therapy, Combination; Female; Follow-Up Studies; Hepa | 1992 |